Drupal.behaviors.print = function(context) {window.print();window.close();}>
Patient Enrichment to Limit PGx Testing for NSCLC Could Lower Costs, but Miss Responders
March 21, 2012
Patient Enrichment to Limit PGx Testing for NSCLC Could Lower Costs, but Miss Responders
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Abbott Challenges 'Incorrect Assumptions' in Cost-Effectiveness Study of Xalkori PGx Testing
March 28, 2012 / Pharmacogenomics Reporter
Focusing on Personalized Medicine, Pfizer Reports PGx Data for Several Oncologics at ASCO
June 9, 2010 / Pharmacogenomics Reporter
Pfizer, Roche Officials Share Lessons Learned from Rx/Dx Co-development of Xalkori and Zelboraf
February 29, 2012 / Pharmacogenomics Reporter
Lab21 Offering Companion Testing to Personalize ALK Inhibitors for NSCLC Patients
February 22, 2012 / Pharmacogenomics Reporter
MDx/CDx Focus: Qiagen; Dako & Amgen; Ventana & Pfizer; Foundation Medicine & Sanofi; and More
January 11, 2012 / Pharmacogenomics Reporter